Product Description
CFI-402411 is a novel, highly orally available immunomodulatory small molecule inhibitor of HPK1 (Hematopoietic Progenitor Kinase 1), a critical regulator of immune cell activation, antigen presentation, and T cell responses to immunosuppressive factors
Mechanisms of Action: HPK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Treadwell Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Hong Kong, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TWT-101 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2024-11-01 |
57% |